Introduction
============

Breast cancer is the most prevalent malignancy worldwide with almost 268,670 cases newly diagnosed in 2018 in the United States only.[@b1-ott-11-8389] Although major progress has been made in cancer treatment, a substantial proportion of the breast cancer patients still experience disease progression, relapse, and reduced overall survival (OS),[@b2-ott-11-8389] and \~70% of them are hormone receptor-positive.[@b3-ott-11-8389] Currently, for hormone receptor-positive advanced breast cancer without visceral crisis, endocrine therapy is regarded as the cornerstone treatment because of the decent disease control and improved quality of life.[@b4-ott-11-8389] However, virtually all the patients will develop disease progression either as de novo resistance or as acquired resistance to the endocrine therapy.[@b5-ott-11-8389] And the management of the endocrine resistance is still a challenging scenario with many unanswered questions.

Fulvestrant, a high selective estrogen receptor down-regulator, is able to bind, block, and accelerate the estrogen receptor degradation.[@b6-ott-11-8389] In the postmenopausal hormone receptor-positive and human epidermal growth factor receptor 2 (HER2)-negative advanced breast patients, recent evidence have validated the role of Fulvestrant monotherapy both in the completely endocrine-naive patients[@b7-ott-11-8389],[@b8-ott-11-8389] and in the patients progressed while receiving or shortly after the completion of endocrine therapy.[@b9-ott-11-8389],[@b10-ott-11-8389] Currently, fulvestrant is approved for the treatment of postmenopausal women with advanced breast cancer after recurrence or first progression following anti-estrogen therapy.[@b11-ott-11-8389]

Nevertheless, the landscape of the treatment of hormone receptor-positive advanced breast cancer is changing rapidly. With increasing understanding of the underlying biological mechanisms of endocrine resistance for metastatic breast cancer (MBC), various clinical trials evaluating fulvestrant in combination with a targeted agent such as cyclin-dependent kinase 4/6 (CDK4/6) inhibitor and PI3K/mTOR pathway inhibitor have been conducted.[@b12-ott-11-8389],[@b13-ott-11-8389] Several fulvestrant-based combination strategies were found to associate with a significant prolonged progression-free survival (PFS) and manageable toxicities in hormone receptor-positive patients with metastatic disease who progressed after a prior endocrine therapy when compared with the fulvestrant alone.[@b12-ott-11-8389]--[@b14-ott-11-8389] However, some other trials failed to demonstrate a better efficacy of the doublet agents.[@b15-ott-11-8389]--[@b17-ott-11-8389] Given these inconsistent results, selecting the optimal choice for these patients becomes complex and somewhat a challenge to the treating clinicians. And the hardest question is whether to choose fulvestrant single-agent therapy or fulvestrant combination therapy, because both of them seem to be reasonable alternatives.[@b4-ott-11-8389]

Herein, our meta-analysis was performed to evaluate the efficacy and safety of fulvestrant combined with a targeted agent compared with fulvestrant monotherapy in those hormone receptor-positive MBC patients progressed on prior endocrine therapy.

Methods
=======

Searching strategy and inclusion criteria
-----------------------------------------

A literature search was conducted to identify Phase II or Phase III randomized controlled trials (RCTs), which compared fulvestrant single agent with fulvestrant plus targeted agents in hormone receptor-positive MBC progressed on previous endocrine therapy from January 1, 1990 to December 10, 2017 from the PubMed, Cochrane library, and Embase. The [ClinicalTrials.gov](http://ClinicalTrials.gov) network (<https://ClinicalTrials.gov>) was also searched for the ongoing studies. In addition, posters and abstracts of the annual meeting of European Society of Medical Oncology and San Antonio Breast Cancer Symposium in the past 10 years were also scanned. The search algorithm was (breast OR mammary) AND (carcinoma OR neoplasm OR tumor OR cancer) AND (metastatic OR advanced OR relapse\*) AND (pretreat\*) AND (fulvestrant). All the reference list of the original papers was reviewed as well.

The inclusion criteria were: (1) prospective Phase II or Phase III RCTs. (2) RCTs comparing fulvestrant monotherapy with the fulvestrant plus a targeted agent in hormone receptor-positive MBC progressing after endocrine therapy. (3) The studies must have sufficient data for extraction, stratification, and calculation.

Quality assessment of the studies
---------------------------------

Two investigators carefully evaluated the quality and the eligibility of the studies independently. Disagreements were resolved after discussion with the third investigator. Using the methods previously reported by Jadad et al,[@b18-ott-11-8389] we assessed quality of the trials according to the following three questions: (1) whether the trial reported an appropriate randomization method (0--2 scores); (2) whether the report included an appropriate blinding method (0--2 scores); and (3) whether the report included an account of the number of withdrawals or dropouts.

Data extraction
---------------

All the data extracted were filled into a standard form by two independent investigators. Discrepancies were resolved through discussion. The following information were extracted: (1) general information of each study, such as journal name, authors' names, and date of publication; (2) characteristics of the patients such as age, sex, race, menopause, HR status, performance status, and tumor burden; (3) study design, such as samples of each group, randomization and blinding method, inclusion and exclusion criteria, type of study endpoints, and follow-up; and (4) data, such as regimens, drug dose, PFS, OS, overall response rate (ORR), clinical benefit rate (CBR), line of therapy, and the pathways inhibited.

Statistical analysis
--------------------

Briefly, pooled HR and 95% CI were employed to appraise the PFS. And pooled risk ratio (RR) and 95% CI were used to evaluate the ORR, CBR, and adverse effects (AEs). HRs, RRs, and 95% CIs were extracted from the original publications directly if they were reported. Otherwise, the original Kaplan--Meier curves of the included studies were read, and the HRs, RRs, and 95% CIs were calculated using the Engauge Digitizer software as previously reported.[@b19-ott-11-8389] This is a free software that can be downloaded from <http://sourceforge.net/projects/digitizer/>. In addition, *χ*^2^-based *Q*-test was used to estimate the heterogeneity between the groups.[@b20-ott-11-8389] Heterogeneity was considered exist when the *P*~heterogeneity~\<0.1 or *I*^2^\>50%, and a random effect model was used. Otherwise, a fixed effect model was used.[@b21-ott-11-8389],[@b22-ott-11-8389] Moreover, publication bias was evaluated using the Egger's test and Begg's test. All the calculation and estimation was conducted using the STATA version 12.0 software (StataCorp LP, College Station, TX, USA). Of note, HR \>1 suggests more PFS events in the combination group compared with single-agent group; RR \<1 suggests more relevant AEs and better treatment response in the combination group, and vice versa.

Results
=======

Study search and eligibility
----------------------------

As shown in [Figure 1](#f1-ott-11-8389){ref-type="fig"}, a total of 1,072 records were identified using our aforementioned searching strategy, and three more studies were added manually from other sources including reference list of original articles, international meeting reports, and reviews. Subsequently, 184 duplicates were removed. And we screened the titles and abstracts of the remaining 891 records, then, 843 were excluded because they were irrelevant publications or reviews. At last, of the 48 potential studies, only 13 studies[@b12-ott-11-8389]--[@b17-ott-11-8389],[@b23-ott-11-8389]--[@b29-ott-11-8389] were included in our qualitative synthesis based on our inclusion criteria.

Study characteristics and patients
----------------------------------

In total, 3,910-hour positive MBC patients progressed on prior endocrine therapy were included in our meta-analysis. Of them, 2,247 patients were randomized to the fulvestrant plus a targeted-agent group and 1,663 patients were randomized to fulvestrant single-agent group. The characteristics of the studies were listed in [Table 1](#t1-ott-11-8389){ref-type="table"}. In the 13 eligible studies, 8 were Phase II and 5 were Phase III RCTs. The standard dose of fulvestrant (500 mg monthly) was administered in 11 studies, and the other 2 included studies[@b16-ott-11-8389],[@b24-ott-11-8389] utilized a suboptimal dose of fulvestrant at 250 mg monthly. As shown in [Table 2](#t2-ott-11-8389){ref-type="table"}, not all patients were HER2 negative and postmenopausal. In detail, 68 (3%) patients were HER2 positive and 224 (10%) patients were premenopausal or perimenopausal, respectively. And it should be noted that all the premenopausal or perimenopausal patients were concurrently given a luteinizing-hormone-releasing-hormone agonist (LHRHa) before the fulvestrant monotherapy or combination therapy.

Progression-free survival
-------------------------

In this meta-analysis, the HRs and 95% CIs for PFS were given directly in 12 original papers included, and the related data in one study were unavailable.[@b15-ott-11-8389] We used the random model to evaluate the pooled PFS because the obvious heterogeneity existed (*I*^2^=72.7%). Our results demonstrated that the addition of a targeted agent to fulvestrant was associated with a prolonged PFS when compared with fulvestrant alone (HR 0.73, 95% CI =0.63--0.86, *P*=0.000, [Figure 2](#f2-ott-11-8389){ref-type="fig"}). In our further subgroup analyses, combination therapy including targeted-agent blocking of CDK4/6 or PI3K/mTOR-signaling pathway contributed to a significantly improved PFS. However, in the VEGF or other inhibitors containing combination regimen, the clinical benefits of the doublet agents were similar to that of fulvestrant alone (CDK4/6 inhibitors: HR 0.51, 95% CI =0.43--0.61, *P*=0.000; VEGF inhibitors, HR 0.92, 95% CI =0.66--1.28, *P*=0.623; PI3K/mTOR inhibitors: HR 0.73, 95% CI =0.66--0.81, *P*=0.000; others: HR 0.93, 95% CI =0.75--1.15, *P*=0.502, [Figure 2](#f2-ott-11-8389){ref-type="fig"}).

Overall response rate
---------------------

The ORR data were unavailable in three studies.[@b23-ott-11-8389],[@b26-ott-11-8389],[@b29-ott-11-8389] Since no significant heterogeneity found (*I*^2^=30.5%), the pooled RR was calculated using fixed model subsequently. Similar to the PFS, the combination therapy also improved ORR compared with fulvestrant alone in the hormone receptor-positive MBC patients progressed on prior endocrine therapy (RR 2.07, 95% CI =1.67--2.58, *P*=0.000, [Figure 3](#f3-ott-11-8389){ref-type="fig"}). In parallel, the subgroup analyses also revealed that fulvestrant plus CDK4/6 inhibitors or PI3K/mTOR inhibitors significantly increased the ORR compared with fulvestrant monotherapy (RR 2.72, 95% CI =1.93--3.83, *P*=0.000 and RR 1.60, 95% CI =1.15--2.23, *P*=0.005, respectively, [Figure 3](#f3-ott-11-8389){ref-type="fig"}).

Toxicities and safety
---------------------

Concerning the toxicities and safety, more side effects and drug-related treatment withdrawals were observed in the combination group in the majority of the included studies. Ten studies reported the grade 3/4 toxicities,[@b12-ott-11-8389],[@b14-ott-11-8389]--[@b17-ott-11-8389],[@b24-ott-11-8389]--[@b28-ott-11-8389] and the pooled analysis showed that the doublet-agent group produced more toxicities although most of them were manageable (RR 3.86, 95% CI =2.66--5.61, *P*=0.000, [Figure 4](#f4-ott-11-8389){ref-type="fig"}). In addition, in the subgroup analyses, those inhibitors targeting CDK4/6, VEGF, or PI3K/mTOR pathway plus fulvestrant led to a higher incidence of grade 3/4 toxicities. And no substantial difference in the grade 3/4 toxicities was observed in other agents combination group compared with fulvestrant alone (CDK4/6 inhibitors: HR 6.90, 95% CI =3.84--12.40, *P*=0.000; VEGF inhibitors: HR 2.80, 95% CI =1.27--6.20, *P*=0.011; PI3K/mTOR inhibitors: HR 3.44, 95% CI =2.50--4.74, *P*=0.000; others: HR 2.49, 95% CI =0.78--7.93, *P*=0.122, [Figure 4](#f4-ott-11-8389){ref-type="fig"}).

Publication bias
----------------

In order to minimize the potential publication bias and to acquire a reliable result, several steps were taken subsequently. First, our literature search strategy was extensive and accurate. Second, we selected the included studies strictly according to our inclusion and exclusion criteria. Finally, we also analyzed the publication bias by several methods. And as is shown in [Figure 5A](#f5-ott-11-8389){ref-type="fig"} and B, no significant publication bias was observed in our meta-analysis (PFS: Begg's test: *P*=0.945, Egger's test: *P*=0.782; ORR: Begg's test: *P*=0.721, Egger's test: *P*=0.681).

Discussion
==========

Currently, the optimal treatment for the hormone receptor-positive MBC patients progressed on previous endocrine therapy has not been well-defined.[@b4-ott-11-8389] First, fulvestrant was approved for the treatment of postmenopausal advanced breast cancer patients after recurrence or first progression following endocrine therapy.[@b30-ott-11-8389],[@b31-ott-11-8389] However, with the landscape of hormone therapy for this population rapidly reshaping, fulvestrant was found to be a good platform for combining agents targeting other pathways involved in the anti-estrogen therapy resistance.[@b23-ott-11-8389] In the PALOMA-3 trial, fulvestrant plus palbociclib (a CDK4/6 inhibitor) significantly extended the PFS compared with fulvestrant single agent irrespective of the prior endocrine sensitivity, HR expression level, and *PI3KCA* mutation status.[@b12-ott-11-8389] And in the BELLE-2 trial, fulvestrant in combination with buparlisib, an oral pan-PI3K inhibitor, also resulted in a superior efficacy compared with fulvestrant alone.[@b13-ott-11-8389] Notably, Lin et al had performed a meta-analysis and compared the efficacy and toxicities of fulvestrant plus targeted agents and fulvestrant alone in this population before.[@b32-ott-11-8389] Unfortunately, only eight studies included and no subgroup analyses performed made the results somewhat problematic and unstable. More importantly, several related trials evaluating the fulvestrant-based combination therapy were reported recently,[@b13-ott-11-8389],[@b14-ott-11-8389],[@b26-ott-11-8389],[@b28-ott-11-8389] and they will definitely affect the pooled results eventually. Therefore, we re-searched the related RCTs and updated the meta-analysis accordingly in order to solve this burning clinical problem.

In this meta-analysis, our results indicated that fulvestrant in combination with a targeted agent appeared to be more efficacious than fulvestrant alone in terms of PFS and ORR. And these superiority were further confirmed in the combination strategies of fulvestrant with CDK4/6 inhibitors or PI3K/mTOR pathway inhibitors in the subgroup analyses ([Figures 2](#f2-ott-11-8389){ref-type="fig"} and [3](#f3-ott-11-8389){ref-type="fig"}). These findings taken together suggested that the superior clinical efficacy of doublet agents might depend on the specific therapeutic combinations. Hence, for the hormone receptor-positive MBC patients, relapse after endocrine therapy, fulvestrant in combination with agents targeting CDK4/6 or PI3K/mTOR represented a promising approach to overcome or at least delay the endocrine resistance. However, although PI3K mutation is already recognized as a predictor of response to anti-PI3K targeted therapy in breast cancer in several trials, the majority of our eligible trials in this meta-analysis did not report the PI3K mutation data directly. Therefore, clinical trials aimed to determine the benefits of fulvestrant in combination with PI3K inhibitor in the PI3K-pathway activated subgroup is warranted in future.

With respect to the toxicities, we also found the grade 3/4 AEs were more common in the combination group irrespective of the targeted agents included ([Figure 4](#f4-ott-11-8389){ref-type="fig"}). Considering the first priority of MBC treatment is to improve or at least maintain the quality of life and to prolong survival,[@b4-ott-11-8389] thus we should be vigilant about the uncontrolled side effects outweighing the marginal clinical benefits. With regret, identification of the most suitable hormone receptor-positive MBC patients who can benefit most from the fulvestrant-based combination therapy is still a significant challenge. The good news is that the circulating tumor DNA (ctDNA), which is released from apoptotic or necrotic tumor cells, seems to be a promising candidate because it reflects the mutation status after relapse.[@b33-ott-11-8389] Moreover, the ctDNA analysis enable us to evaluate the mutational and expression changes which reflect the patient-specific dynamic tumor landscapes in a repetitive and non-invasive way.[@b34-ott-11-8389] And our findings merit further investigation into the relationship between the ctDNA mutation status and the clinical benefit of the combination therapy in these patients.

Honestly, there are several limitations in the present meta-analysis, and it should be cautious when interpreting the results. First, different combination strategies, treatment regimens, drug doses, and patient selections inevitably imposed heterogeneity to the pooled analyses. For instance, not all patients included in the meta-analysis were HER2 negative (3% HER2 positive) and postmenopausal (10% perimenopausal or premenopausal). Since HER2 pathway is able to crosstalk with the estrogen-signaling pathway and is involved in the endocrine resistance,[@b35-ott-11-8389],[@b36-ott-11-8389] the HER2-positive population and anti-HER2 therapy themselves will definitely act as relative confounding factors in turn. Moreover, for the perimenopausal and premenopausal patients, we cannot rule out the possibility that the administered LHRHa may affect the final estimation. After all, LHRHa itself was reported as an effective endocrine approach in breast cancer.[@b37-ott-11-8389],[@b38-ott-11-8389] Second, the line of therapy, metastatic sites, tumor burden, prior anti-estrogen drugs, and anti-estrogen treatment sequence in these eligible studies were also heterogeneous. And the sensitivities to previous endocrine therapy were also not homogeneous. Notably, compared with hormone receptor-positive MBC patients with visceral metastases, fulvestrant was believed to be more efficacious for those patients with nonvisceral metastases only.[@b7-ott-11-8389] Thus, the different metastatic sites and tumor burden of patients in these included studies may also contribute to the observed heterogeneity. Third, not all the included studies administered a standard dose of fulvestrant (500 mg monthly) to the patients. Fulvestrant is a pure, steroidal ER antagonist, and the inhibitory effect of the estrogen-signaling pathway is dose dependent. And the CONFIRM trial has revealed a superior effect of 500 mg fulvestrant when compared with 250 mg fulvestrant in terms of PFS and OS.[@b39-ott-11-8389] Therefore, the nonstandard fulvestrant dose may partly result in bias of our findings as well. Finally, the present meta-analysis was not conducted based on the individual patient data but on the HR and 95% CIs of each study extracted. And the sample size was relatively limited, which made it incapable of comparing some kinds of infrequent toxicities between those groups. Despite all these limitations, our study is a meaningful meta-analysis to evaluate the fulvestrant plus a targeted agent in the hormone receptor-positive MBC progressed on previous endocrine therapy.

In conclusion, we validated the combination of a targeted agent with fulvestrant was associated with a superior benefit and more frequent AEs when compared with fulvestrant alone. This warrants that further studies focus on identification of those patients who will derive benefits from the combination strategy to aid treatment decisions.
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**Abbreviations:** PFS, progression-free survival; ORR, overall response rate.](ott-11-8389Fig5){#f5-ott-11-8389}

###### 

Characteristics of 13 trials eligible for meta-analysis

  Author                              Year   Phase   Regimens                Dose of FUL   Pathways inhibited   Targeted agents   Jadad score
  ----------------------------------- ------ ------- ----------------------- ------------- -------------------- ----------------- -------------
  Sledge GW[@b14-ott-11-8389]         2017   III     FUL + abemaciclib/FUL   500 mg        CDK4/6               Abemaciclib       3
  Zaman K[@b15-ott-11-8389]           2015   II      FUL + selumetinib/FUL   500 mg        MEK1/2               Selumetinib       3
  Adelson K[@b23-ott-11-8389]         2016   II      FUL + bortezomib/FUL    500 mg        Proteasome           Bortezomib        3
  Cristofanilli M[@b12-ott-11-8389]   2016   III     FUL + palbociclib/FUL   500 mg        CDK4/6               Palbociclib       3
  Hyams DM[@b24-ott-11-8389]          2013   II      FUL + cediranib/FUL     250 mg        VEGF                 Cediranib         3
  Burstein HJ[@b16-ott-11-8389]       2014   III     FUL + lapatinib/FUL     250 mg        HER1, HER2           Lapatinib         3
  Clemons MJ[@b17-ott-11-8389]        2014   II      FUL + vande/FUL         500 mg        VEGF, EGFR           Vandetanib        3
  Musolino A[@b25-ott-11-8389]        2017   II      FUL + dovitinib/FUL     500 mg        FGFR                 Dovitinib         3
  Baselga J[@b13-ott-11-8389]         2017   III     FUL + buparlisib/FUL    500 mg        PI3K                 Buparlisib        3
  Kornblum NS[@b26-ott-11-8389]       2016   II      FUL + everolimus/FUL    500 mg        mTOR                 Everolimus        3
  Krop IE[@b27-ott-11-8389]           2016   II      FUL + pictilisib/FUL    500 mg        PI3K                 Pictilisib        3
  Di Leo A[@b28-ott-11-8389]          2017   III     FUL + buparlisib/FUL    500 mg        PI3K                 Buparlisib        3
  Robertson JF[@b29-ott-11-8389]      2013   II      FUL + ganitinib/FUL     500 mg        IGF-1/IGF-2          Ganitumab         3

**Abbreviations:** CDK4/6, cyclin-dependent kinase 4/6; FUL, fulvestrant; HER1, human epidermal growth factor receptor 1; HER2, human epidermal growth factor receptor 2.

###### 

Patients characteristics and outcomes in this meta-analysis

  Author                              No of patients   Postmenopausal status (%)   HER2 status   ORR (doublet agents vs single agent)   Median PFS (months, doublet agents vs single agent)   Median OS (months, doublet agents vs single agent)
  ----------------------------------- ---------------- --------------------------- ------------- -------------------------------------- ----------------------------------------------------- ----------------------------------------------------
  Sledge GW[@b14-ott-11-8389]         669              83                          --            35% vs 16%                             16.4 vs 9.3                                           --
  Zaman K[@b15-ott-11-8389]           42               100                         --            5% vs 15%                              3.7 vs 5.6                                            22.9 vs 19.4
  Adelson K[@b23-ott-11-8389]         116              100                         --            --                                     2.73 vs 2.69                                          --
  Cristofanilli M[@b12-ott-11-8389]   521              79                          --            19% vs 9%                              9.5 vs 4.6                                            --
  Hyams DM[@b24-ott-11-8389]          62               100                         NA            22% vs 8%                              7.4 vs 3.7                                            --
  Burstein HJ[@b16-ott-11-8389]       291              100                         ±18%          20% vs 9%                              4.7 vs 3.8                                            30 vs 26.4
  Clemons MJ[@b17-ott-11-8389]        129              100                         ±5%           0% vs 7%                               5.8 vs 4.8                                            31 vs --
  Musolino A[@b25-ott-11-8389]        97               100                         --            28% vs 10%                             5.5 vs 5.5                                            --
  Baselga J[@b13-ott-11-8389]         1,147            100                         --            12% vs 8%                              6.9 vs 5.0                                            --
  Kornblum NS[@b26-ott-11-8389]       130              100                         --            --                                     10.4 vs 5.1                                           --
  Krop IE[@b27-ott-11-8389]           168              100                         --            8% vs 6%                               6.6 vs 5.1                                            --
  Di Leo A[@b28-ott-11-8389]          432              100                         --            8% vs 2%                               3.9 vs 1.8                                            --
  Robertson JF[@b29-ott-11-8389]      156              100                         ±7%           --                                     3.7 vs 5.4                                            --

**Abbreviations:** HER2, human epidermal growth factor receptor 2; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; NA, not available.
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